Genetic Analysis AS (XSAT:GEAN.TO.2) EBIT : kr-23.56 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Genetic Analysis AS EBIT?

Genetic Analysis AS's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was kr-6.61 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was kr-23.56 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Genetic Analysis AS's annualized ROC % for the quarter that ended in Dec. 2023 was -185.85%. Genetic Analysis AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -412.67%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Genetic Analysis AS EBIT Historical Data

The historical data trend for Genetic Analysis AS's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Analysis AS EBIT Chart

Genetic Analysis AS Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

-6.73

-21.93

-28.87

-28.16

-23.56

Genetic Analysis AS Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial										-7.77	-7.27	-5.42	-4.26	-6.61

Competitive Comparison of Genetic Analysis AS's EBIT

For the Diagnostics & Research subindustry, Genetic Analysis AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genetic Analysis AS's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Analysis AS's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Genetic Analysis AS's EV-to-EBIT falls into.

Genetic Analysis AS EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-23.56 Mil.

Genetic Analysis AS (XSAT:GEAN.TO.2) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Genetic Analysis AS's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-64.2 * ( 1 - 0% )	/	( (34.195	+	34.894)	/ 2 )
=	-64.2	/	34.5445
=	-185.85 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	42.949	-	0.786	-	( 9.768	-	max(0, 9.634	-	17.602	+	9.768	))
=	34.195

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	53.49	-	5.585	-	( 15.279	-	max(0, 16.045	-	29.056	+	15.279	))
=	34.894

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Genetic Analysis AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-26.444	/	( ( (6.628 + max(-5.57, 0))	+	(6.188 + max(-9.119, 0)) )	/	2 )
=	-26.444	/	( ( 6.628	+	6.188 )	/	2 )
=	-26.444	/	6.408
=	-412.67 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2.896	+	1.168	+	0)	-	(0.786	+	0	+	8.848)
=	-5.57

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.898	+	1.539	+	1.519)	-	(5.585	+	0	+	8.49)
=	-9.119

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Genetic Analysis AS's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-23.564	/	0.000
	=	%

Genetic Analysis AS EBIT Related Terms

Thank you for viewing the detailed overview of Genetic Analysis AS's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Analysis AS (XSAT:GEAN.TO.2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Analysis AS (XSAT:GEAN.TO.2) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

GEAN:Sweden

Address

Kabelgata 8, Oslo, NOR, 0580

Website

https://www.genetic-analysis.com

Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering innovative diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients.

Genetic Analysis AS (XSAT:GEAN.TO.2) Headlines

No Headlines